# Effect Modification of Trimethylamine N-Oxide and Lipoprotein Insulin Resistance with Post-Transplantation Diabetes After Liver Transplant

**Authors:** Mateo Chvatal-Medina, Yakun Li, Adrian Post, Margery A. Connelly, Han Moshage, Stephan J. L. Bakker, Vincent E. de Meijer, Hans Blokzijl, Robin P. F. Dullaart

PMC · DOI: 10.3390/ijms27041959 · International Journal of Molecular Sciences · 2026-02-18

## TL;DR

This study finds that two biomarkers, TMAO and LP-IR, are linked to increased risk of diabetes after liver transplants, with their combined effect being even stronger.

## Contribution

The study identifies a novel interaction between TMAO and LP-IR in predicting post-transplant diabetes.

## Key findings

- Higher TMAO and LP-IR scores are independently associated with increased PTDM risk.
- The combination of elevated TMAO and LP-IR amplifies the risk of PTDM.
- Time-to-event analysis confirms the interaction effect between TMAO and LP-IR.

## Abstract

Post-transplant diabetes mellitus (PTDM) is a common complication after liver transplantation. Trimethylamine N-oxide (TMAO), a microbiota-derived metabolite, has been linked to insulin resistance, but epidemiological findings on type 2 diabetes remain inconsistent. The Lipoprotein Insulin Resistance (LP-IR) score is a nuclear magnetic resonance (NMR)-derived marker of insulin resistance, yet its role in PTDM and interaction with TMAO are unknown. Three hundred sixty-seven (367) liver transplant recipients (LTRs) from the TransplantLines cohort were studied. Baseline TMAO and LP-IR score were quantified by NMR spectroscopy. Incident PTDM was defined by international criteria. Associations were tested using logistic regression and Cox proportional regression analysis. Effect modification was tested with interaction terms. Thirty-one out of 246 LTRs at risk developed PTDM after a median follow-up of 7.1 years. Higher TMAO (OR 2.14, p = 0.015) and LP-IR score (OR 1.66, p = 0.015) were associated with increased PTDM risk after adjustment for eGFR and immunosuppressant use. A positive interaction was present (p = 0.029) with risk amplification when both biomarkers were elevated. TMAO’s association with PTDM was strongest at high LP-IR (90th percentile; OR 3.20, p = 0.005), and LP-IR’s association was strongest at high TMAO (90th percentile; OR 2.56, p = 0.002). Time-to-event analysis confirmed these findings. The independent and positive interaction of TMAO and LP-IR with PTDM in LTRs would suggest a pro-diabetic action of TMAO that depends on insulin resistance.

## Linked entities

- **Chemicals:** Trimethylamine N-oxide (PubChem CID 1145), doxorubicin (PubChem CID 31703)
- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, FMO3 (flavin containing dimethylaniline monoxygenase 3) [NCBI Gene 2328] {aka FMOII, TMAU, dJ127D3.1}, CABIN1 (calcineurin binding protein 1) [NCBI Gene 23523] {aka CAIN, KB-318B8.7, PPP3IN}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** -cell dysfunction (MESH:D002292), glucose tolerance (MESH:D018149), metabolic (MESH:D008659), LTRs (MESH:D017093), type 2 diabetes (MESH:D003924), obesity (MESH:D009765), LP-IR (MESH:D007333), cardiovascular disease (MESH:D002318), post- (MESH:D000094025), DM (MESH:D003920), cardiovascular and infection (MESH:D053821), Hypertension (MESH:D006973), death (MESH:D003643), metabolic complication (MESH:D020739), injury to (MESH:D014947), chronic inflammation (MESH:D007249), hyperglycemia (MESH:D006943), IR (MESH:C537629)
- **Chemicals:** creatinine (MESH:D003404), glucose (MESH:D005947), TMA (MESH:C023336), LP (MESH:D008070), lipid (MESH:D008055), ATP (MESH:D000255), steroid (MESH:D013256), choline (MESH:D002794), EDTA (MESH:D004492), tacrolimus (MESH:D016559), TMAO (MESH:C005855), carnitine (MESH:D002331), cyclosporine (MESH:D016572), betaine (MESH:D001622), 1H (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940386/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940386/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940386/full.md

---
Source: https://tomesphere.com/paper/PMC12940386